BioCentury | Aug 16, 2018
Distillery Therapeutics

Dermatology; pulmonary

...A. et al. Nat. Commun. ; published online Aug. 14, 2018 doi:10.1038/s41467-018-05768-3 CONTACT: Jingang Huang, University of Erlangen-Nuremberg...
...Erlangen, Germany email: Jingang.Huang@uk-erlangen.de CONTACT: Jörg H. W. Distler, same affiliation as above email: joerg.distler@uk-erlangen.de Claire Quang University of Erlangen-Nuremberg Src...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Autoimmune disease

...2017 doi:10.1038/nm.4373 CONTACT: Andreas Ramming, University of Erlangen-Nuremerg and Universitätsklinikum Erlangen, Erlangen, Germany email: andreas.ramming@uk-erlangen.de Claire Quang University of Erlangen-Nuremberg Interleukin-9...
BioCentury | May 16, 2017
Distillery Therapeutics

Cancer

...University Erlangen-Nuremberg, Erlangen, Germany email: marc.stemmler@fau.de CONTACT: Thomas Brabletz, same affiliation as above email: thomas.brabletz@fau.de Winnie Pong University of Erlangen-Nuremberg Zinc...
BioCentury | Nov 9, 2016
Distillery Therapeutics

Hepatic

...published online Oct. 17, 2016 doi:10.1172/JCI87545 CONTACT: Stefan Wirtz, University of Erlangen-Nuremberg, Erlangen, Germany email: stefan.wirtz@uk-erlangen.de Esme Gaisford University of Erlangen-Nuremberg Mixed-lineage...
BioCentury | Sep 1, 2016
Distillery Therapeutics

Therapeutics: µ opioid receptor (MOR; OPRM1); G protein α inhibiting activity polypeptide 1 (GNAI1)

...CONTACT: Brian Kobilka, Stanford University School of Medicine, Stanford, Calif. email: kobilka@stanford.edu CONTACT: Peter Gmeiner, University of Erlangen-Nuremberg...
BioCentury | Sep 1, 2016
Targets & Mechanisms

Biased against pain

...San Francisco (UCSF), University of North Carolina at Chapel Hill , Stanford University and the University of Erlangen-Nuremberg...
...Trevena Inc. (NASDAQ:TRVN), King of Prussia, Pa. University of California San Francisco, San Francisco, Calif. University of Erlangen-Nuremberg...
BioCentury | Aug 4, 2016
Distillery Techniques

Techniques: Neurotensin (NTS)-based PET imaging agents for diagnosing and monitoring treatment responses of neurotensin receptor 1 (NTSR1)-positive tumors

Imaging TECHNOLOGY: PET Neurotensin-based PET imaging agents could help diagnose and monitor treatment-response for NTSR1-positive cancers. Two agents, consisting of a six-amino acid peptide derived from the N-terminus of neurotensin conjugated via linkers to a...
BioCentury | Apr 7, 2016
Distillery Therapeutics

Therapeutics: Peptidyl arginine deiminase type IV (PAD4; PADI4)

...Leppkes, M. et al. Nat. Commun.; published online March 11, 2016 doi:10.1038/ncomms10973 CONTACT: Moritz Leppkes, University of Erlangen-Nuremberg...
BioCentury | Mar 5, 2015
Distillery Therapeutics

Therapeutics: Nuclear receptor subfamily 4 group A member 1 (NR4A1, NGFI-B, NURR77)

...K. et al. Nat. Med.; published online Jan. 12, 2015 doi:10.1038/nm.3777 CONTACT: Jörg H.W. Distler, University of Erlangen-Nuremberg...
BioCentury | Jan 12, 2015
Emerging Company Profile

Targeting transcription regulators

...Frédéric Cren University collaborators: Institut Curie , Paris Descartes University , Imperial College London , University of Erlangen-Nuremberg...
Items per page:
1 - 10 of 41
BioCentury | Aug 16, 2018
Distillery Therapeutics

Dermatology; pulmonary

...A. et al. Nat. Commun. ; published online Aug. 14, 2018 doi:10.1038/s41467-018-05768-3 CONTACT: Jingang Huang, University of Erlangen-Nuremberg...
...Erlangen, Germany email: Jingang.Huang@uk-erlangen.de CONTACT: Jörg H. W. Distler, same affiliation as above email: joerg.distler@uk-erlangen.de Claire Quang University of Erlangen-Nuremberg Src...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Autoimmune disease

...2017 doi:10.1038/nm.4373 CONTACT: Andreas Ramming, University of Erlangen-Nuremerg and Universitätsklinikum Erlangen, Erlangen, Germany email: andreas.ramming@uk-erlangen.de Claire Quang University of Erlangen-Nuremberg Interleukin-9...
BioCentury | May 16, 2017
Distillery Therapeutics

Cancer

...University Erlangen-Nuremberg, Erlangen, Germany email: marc.stemmler@fau.de CONTACT: Thomas Brabletz, same affiliation as above email: thomas.brabletz@fau.de Winnie Pong University of Erlangen-Nuremberg Zinc...
BioCentury | Nov 9, 2016
Distillery Therapeutics

Hepatic

...published online Oct. 17, 2016 doi:10.1172/JCI87545 CONTACT: Stefan Wirtz, University of Erlangen-Nuremberg, Erlangen, Germany email: stefan.wirtz@uk-erlangen.de Esme Gaisford University of Erlangen-Nuremberg Mixed-lineage...
BioCentury | Sep 1, 2016
Distillery Therapeutics

Therapeutics: µ opioid receptor (MOR; OPRM1); G protein α inhibiting activity polypeptide 1 (GNAI1)

...CONTACT: Brian Kobilka, Stanford University School of Medicine, Stanford, Calif. email: kobilka@stanford.edu CONTACT: Peter Gmeiner, University of Erlangen-Nuremberg...
BioCentury | Sep 1, 2016
Targets & Mechanisms

Biased against pain

...San Francisco (UCSF), University of North Carolina at Chapel Hill , Stanford University and the University of Erlangen-Nuremberg...
...Trevena Inc. (NASDAQ:TRVN), King of Prussia, Pa. University of California San Francisco, San Francisco, Calif. University of Erlangen-Nuremberg...
BioCentury | Aug 4, 2016
Distillery Techniques

Techniques: Neurotensin (NTS)-based PET imaging agents for diagnosing and monitoring treatment responses of neurotensin receptor 1 (NTSR1)-positive tumors

Imaging TECHNOLOGY: PET Neurotensin-based PET imaging agents could help diagnose and monitor treatment-response for NTSR1-positive cancers. Two agents, consisting of a six-amino acid peptide derived from the N-terminus of neurotensin conjugated via linkers to a...
BioCentury | Apr 7, 2016
Distillery Therapeutics

Therapeutics: Peptidyl arginine deiminase type IV (PAD4; PADI4)

...Leppkes, M. et al. Nat. Commun.; published online March 11, 2016 doi:10.1038/ncomms10973 CONTACT: Moritz Leppkes, University of Erlangen-Nuremberg...
BioCentury | Mar 5, 2015
Distillery Therapeutics

Therapeutics: Nuclear receptor subfamily 4 group A member 1 (NR4A1, NGFI-B, NURR77)

...K. et al. Nat. Med.; published online Jan. 12, 2015 doi:10.1038/nm.3777 CONTACT: Jörg H.W. Distler, University of Erlangen-Nuremberg...
BioCentury | Jan 12, 2015
Emerging Company Profile

Targeting transcription regulators

...Frédéric Cren University collaborators: Institut Curie , Paris Descartes University , Imperial College London , University of Erlangen-Nuremberg...
Items per page:
1 - 10 of 41